MCID: AST007
MIFTS: 51

Astrocytoma

Categories: Cancer diseases, Neuronal diseases

Aliases & Classifications for Astrocytoma

MalaCards integrated aliases for Astrocytoma:

Name: Astrocytoma 12 76 29 55 6 44 15 73
Cerebral Astrocytoma 12 73
Astrocytoma, No Icd-O Subtype 12
Astrocytoma of Cerebrum 12
Astrocytoma of Brain 12
Astrocytic Tumor 12
Astroglioma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3069
MeSH 44 D001254

Summaries for Astrocytoma

Disease Ontology : 12 A malignant glioma that is has material basis in astocyte cells, a type of star-shaped glial cell, located in the cerebrum.

MalaCards based summary : Astrocytoma, also known as cerebral astrocytoma, is related to glioblastoma and glioma. An important gene associated with Astrocytoma is FGFR1 (Fibroblast Growth Factor Receptor 1). The drugs Afinitor and Temodar have been mentioned in the context of this disorder. Affiliated tissues include brain, spinal cord and t cells.

Wikipedia : 76 Astrocytomas are a type of cancer of the brain. They originate in a particular kind of glial cells,... more...

Related Diseases for Astrocytoma

Diseases in the Astrocytoma family:

Juvenile Astrocytoma

Diseases related to Astrocytoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 295)
# Related Disease Score Top Affiliating Genes
1 glioblastoma 32.7 FGFR1 H19 HOTAIR HOXA-AS3 MIR21 SNHG7
2 glioma 32.4 CASC2 FGFR1 H19 HOTAIR MIR21
3 neuroblastoma 32.0 FGFR1 H19 HOTAIR MIR106A PTPN11 SNHG1
4 leukemia, acute myeloid 31.1 CCDC26 HOTAIR MIR21 PTPN11
5 prostate cancer 30.9 CASC2 FGFR1 H19 HOTAIR MIR106A MIR21
6 breast cancer 30.9 CASC2 CCDC26 FGFR1 H19 HOTAIR LINC01089
7 thyroid cancer, nonmedullary, 1 30.4 H19 HOTAIR MIR21
8 pilocytic astrocytoma 12.5
9 fibrillary astrocytoma 12.4
10 grade iii astrocytoma 12.4
11 subependymal giant cell astrocytoma 12.3
12 melanoma-astrocytoma syndrome 12.3
13 spinal cord astrocytoma 12.0
14 cerebellar astrocytoma 12.0
15 gemistocytic astrocytoma 12.0
16 pilomyxoid astrocytoma 12.0
17 juvenile pilocytic astrocytoma 12.0
18 protoplasmic astrocytoma 12.0
19 pilocytic astrocytoma of cerebellum 12.0
20 juvenile astrocytoma 12.0
21 optic nerve astrocytoma 12.0
22 childhood pilocytic astrocytoma 12.0
23 diencephalic astrocytomas 12.0
24 mixed oligodendroglioma-astrocytoma 12.0
25 desmoplastic infantile astrocytoma 11.9
26 childhood cerebral astrocytoma 11.9
27 desmoplastic infantile astrocytoma/ganglioglioma 11.9
28 glioma susceptibility 1 11.8
29 childhood optic tract astrocytoma 11.8
30 mixed astrocytoma-ependymoma 11.8
31 pineal gland astrocytoma 11.8
32 adult brainstem astrocytoma 11.8
33 childhood brainstem astrocytoma 11.8
34 mixed astrocytoma-ependymoma-oligodendroglioma 11.8
35 cauda equina intradural extramedullary astrocytoma 11.7
36 cerebellar astrocytoma, childhood 11.7
37 oligoastrocytoma 11.7
38 tuberous sclerosis 11.3
39 kidney cancer 11.3 H19 HOTAIR MIR106A MIR21
40 osteogenic sarcoma 11.3 CASC2 H19 HOTAIR SNHG1
41 glioblastoma multiforme 11.3
42 esophageal cancer 11.3 CASC2 H19 HOTAIR MIR106A MIR21 SBF2-AS1
43 adamantinoma of long bones 11.2 CASC2 FGFR1 H19 HOTAIR
44 gastric cancer 11.2 CASC2 ENTPD1-AS1 H19 HOTAIR MIR106A MIR21
45 myeloproliferative neoplasm 11.2 FGFR1 H19 PTPN11
46 diencephalic syndrome 11.2
47 subependymoma 11.2
48 pancreatic ductal adenocarcinoma 11.2 H19 HOTAIR MIR21
49 pancreatic cancer 11.2 CASC2 CCDC26 H19 HOTAIR MIR106A MIR21
50 li-fraumeni syndrome 11.2

Graphical network of the top 20 diseases related to Astrocytoma:



Diseases related to Astrocytoma

Symptoms & Phenotypes for Astrocytoma

Drugs & Therapeutics for Astrocytoma

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Afinitor 18 49 EVEROLIMUS Novartis March 2009
2
Temodar 18 49 TEMOZOLOMIDE Schering-Plough August 1999

Drugs for Astrocytoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 597)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dacarbazine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 4342-03-4 5351166
2
Temozolomide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 85622-93-1 5394
3
Everolimus Approved Phase 4,Phase 2,Phase 3,Phase 1 159351-69-6 6442177
4
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 22916-47-8 4189
5
Sirolimus Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 53123-88-9 5284616 6436030 46835353
6
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 1994-09-7, 94-09-7 2337
7 tannic acid Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Not Applicable
8 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
9 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
10 Anti-Bacterial Agents Phase 4,Phase 2,Phase 3,Phase 1
11 Antibiotics, Antitubercular Phase 4,Phase 2,Phase 3,Phase 1
12 Antifungal Agents Phase 4,Phase 2,Phase 3,Phase 1
13 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
14 Immunosuppressive Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
15
Carboplatin Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 41575-94-4 10339178 498142 38904
16
Cyclophosphamide Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 50-18-0, 6055-19-2 2907
17
Etoposide Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 33419-42-0 36462
18
Melphalan Approved Phase 2, Phase 3,Phase 1 148-82-3 4053 460612
19
Thiotepa Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 52-24-4 5453
20
Carmustine Approved, Investigational Phase 3,Phase 1,Phase 2,Not Applicable 154-93-8 2578
21
Tranexamic Acid Approved Phase 3 1197-18-8 5526
22
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
23
Ifosfamide Approved Phase 3,Phase 2,Phase 1 3778-73-2 3690
24
Levoleucovorin Approved, Investigational Phase 3,Phase 2,Phase 1 68538-85-2
25
Lomustine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 13010-47-4 3950
26
Mechlorethamine Approved, Investigational Phase 3,Phase 2,Phase 1 51-75-2 4033
27
Methotrexate Approved Phase 3,Phase 2,Not Applicable 1959-05-2, 59-05-2 126941
28
Prednisone Approved, Vet_approved Phase 3,Phase 2 53-03-2 5865
29
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 2068-78-2, 57-22-7 5978
30
Procarbazine Approved, Investigational Phase 3,Phase 2,Phase 1 671-16-9 4915
31
Trioxsalen Approved Phase 3,Phase 2,Phase 1 3902-71-4 5585
32
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1 135968-09-1
33
Citalopram Approved Phase 2, Phase 3 59729-33-8 2771
34
Irinotecan Approved, Investigational Phase 2, Phase 3,Phase 1,Early Phase 1 97682-44-5, 100286-90-6 60838
35
Bevacizumab Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable,Early Phase 1 216974-75-3
36
Ethanol Approved Phase 2, Phase 3,Phase 1,Early Phase 1 64-17-5 702
37
Aminolevulinic acid Approved Phase 3,Phase 1,Phase 2,Not Applicable 106-60-5 137
38
Sunitinib Approved, Investigational Phase 2, Phase 3,Phase 1,Early Phase 1 341031-54-7, 557795-19-4 5329102
39
Hydroxychloroquine Approved Phase 2, Phase 3,Phase 1 118-42-3 3652
40
Thioguanine Approved Phase 3,Phase 2 154-42-7 2723601
41
Hydroxyurea Approved Phase 3,Phase 2,Phase 1 127-07-1 3657
42
Isotretinoin Approved Phase 3,Phase 2,Phase 1 4759-48-2 5538 5282379
43
Vorinostat Approved, Investigational Phase 2, Phase 3,Phase 1,Not Applicable 149647-78-9 5311
44
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
45
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 50-02-2 5743
46
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
47
Ondansetron Approved Phase 3 99614-02-5 4595
48
Donepezil Approved Phase 3,Phase 2,Early Phase 1 120014-06-4 3152
49
chloroquine Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 54-05-7 2719
50
Leflunomide Approved, Investigational Phase 3,Phase 2 75706-12-6 3899

Interventional clinical trials:

(show top 50) (show all 1435)
# Name Status NCT ID Phase Drugs
1 Standard Temodal (Temozolomide) Regimen Versus Standard Regimen Plus Early Postsurgery Temodal for Newly Diagnosed Glioblastoma Multiforme (Study P05572) Completed NCT00686725 Phase 4 Temozolomide
2 Assessment of Optune Therapy for Patients With Newly Diagnosed Glioblastoma Using Advanced MRI Recruiting NCT03297125 Phase 4
3 Supra-early Post-Surgery Chemotherapy in the Treatment on GBM Patients Recruiting NCT02520635 Phase 4 supra-early TEMODAL® chemotherapy;standard TEMODAL® chemotherapy
4 Long-term Follow-up for Growth and Development of Pediatric Patients From CRAD001M2301 Active, not recruiting NCT02338609 Phase 4 Everolimus;Envirolimus drug class as prescribed by Physician
5 Post-approval Study of NovoTTF-100A in Recurrent GBM Patients Terminated NCT01756729 Phase 4
6 Stem Cell Transplant for High Risk Central Nervous System (CNS) Tumors Unknown status NCT00179803 Phase 2, Phase 3
7 Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Newly Diagnosed Malignant Glioma Unknown status NCT01656980 Phase 3 Carmustine
8 Efficacy of RAD001/Everolimus in Autism and NeuroPsychological Deficits in Children With Tuberous Sclerosis Complex Unknown status NCT01730209 Phase 2, Phase 3 Everolimus;Placebo
9 Efficacy of Tranexamic Acid in Brain Tumor Resections Unknown status NCT01655927 Phase 3 Tranexamic Acid;Placebo: Saline
10 Combination Chemotherapy and Radiation Therapy With or Without Methotrexate in Treating Young Patients With Newly Diagnosed Gliomas Unknown status NCT00278278 Phase 3 cisplatin;etoposide;ifosfamide;lomustine;methotrexate;prednisone;vincristine sulfate
11 Carboplatin Plus Vincristine in Treating Children and Adolescents With Low Grade Glioma Unknown status NCT00003015 Phase 3 carboplatin;vincristine sulfate
12 Surgery, Radiation Therapy, and Chemotherapy With or Without Photodynamic Therapy in Treating Patients With Newly Diagnosed or Recurrent Malignant Supratentorial Gliomas Unknown status NCT00003788 Phase 3 carmustine;lomustine;porfimer sodium;procarbazine hydrochloride
13 Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors Unknown status NCT00392886 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide;methotrexate;temozolomide;thiotepa;vincristine sulfate
14 The Effect of Escitalopram on Mood, Quality of Life and Cognitive Functioning in Glioblastoma Patients Unknown status NCT02623231 Phase 2, Phase 3 Escitalopram;placebo
15 Metronomic Temozolamide in Patients With Recurrent Glioblastoma Unknown status NCT01308632 Phase 2, Phase 3 Temozolamide, irinotecan
16 Efficacy and Safety of Everolimus (RAD001) in Patients of All Ages With Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex (TSC)(EXIST-1) Completed NCT00789828 Phase 3 Everolimus;Placebo
17 Efficacy and Safety of Temodal vs Semustine in Subjects With Recurrent Glioblastoma or Anaplastic Astrocytoma (Study P03644) Completed NCT00335075 Phase 3 Temozolomide;Semustine
18 Radiation Therapy Combined With Chemotherapy in Treating Patients With Anaplastic Astrocytoma or Mixed Gliomas Completed NCT00004259 Phase 3 BCNU 80mg/m2;TMZ 200mg/m2;CCNU;BCNU 150mg/m2;BCNU 200mg/m2;TMZ 150mg/m2 six 6-week cycles;TMZ 150mg/m2 six 8-week cycles
19 Phase III Trial of Primary Radio- or Chemotherapy in Malignant Astrocytoma of the Elderly Completed NCT01502241 Phase 3 Temozolomide
20 Radiotherapy for Malignant Astrocytomas in the Elderly Completed NCT00430911 Phase 3 Radiotherapy
21 Combination Chemotherapy in Treating Children With Progressive Brain Tumors Completed NCT00002944 Phase 3 carboplatin;lomustine;procarbazine hydrochloride;thioguanine;vincristine sulfate
22 Radiation Therapy in Treating Patients With Brain Cancer Completed NCT00002620 Phase 3 carmustine;chemotherapy;mitolactol
23 Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma Completed NCT00154375 Phase 3 Imatinib mesylate;Hydroxyurea
24 Temozolomide Compared to Procarbazine, Lomustine, and Vincristine in Treating Patients With Recurrent Malignant Glioma Completed NCT00052455 Phase 3 lomustine;procarbazine hydrochloride;temozolomide;vincristine sulfate
25 Randomized Phase III Study of Sequential Radiochemotherapy of Anaplastic Glioma With PCV or Temozolomide Completed NCT00717210 Phase 3 Temozolomide
26 High Light and Low Light Dose PDT in Glioma Completed NCT00118222 Phase 3 porfimer sodium
27 High-Dose Chemotherapy Plus Autologous Stem Cell Transplantation Compared With Intermediate-Dose Chemotherapy Plus Autologous Stem Cell Transplantation With or Without Isotretinoin in Treating Young Patients With Recurrent High-Grade Gliomas Completed NCT00078988 Phase 3 carboplatin;etoposide;isotretinoin;thiotepa
28 Observation or Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Low-Grade Glioma Completed NCT00003375 Phase 2, Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
29 Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma Completed NCT01236560 Phase 2, Phase 3 Temozolomide;Vorinostat
30 Radiation Therapy or Temozolomide in Treating Patients With Gliomas Completed NCT00182819 Phase 3 temozolomide
31 Standard Radiation Therapy With or Without Stereotactic Radiation Therapy in Treating Patients With Glioma Completed NCT00003916 Phase 3
32 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
33 Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy Completed NCT01346267 Phase 3
34 Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo
35 An Open-Labeled, Extended-Use of XERECEPT (hCRF) for Patients in Studies NTI 0302, 0303, or Other Designated Studies Completed NCT00226655 Phase 3 hCRF [XERECEPT (corticorelin acetate injection)]
36 XERECEPT® (hCRF) for Patients Requiring Dexamethasone to Treat Edema Associated With Brain Tumors Completed NCT00088166 Phase 3 hCRF;placebo hCRF
37 Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM) Completed NCT00790400 Phase 3 Everolimus (RAD001);Everolimus Placebo
38 Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma Completed NCT01480479 Phase 3 Rindopepimut (CDX-110) with GM-CSF;Temozolomide;KLH
39 Short Course vs. Standard Course Radiotherapy in Elderly and/or Frail Patients With Glioblastoma Multiforme Completed NCT01450449 Phase 3
40 Conventional Adjuvant Temozolomide With Dose Intensive Temozolomide in Patients With Newly Diagnosed Glioblastoma Completed NCT01364064 Phase 3 TMZ
41 Efficacy and Safety Study of Lomustine/Temozolomide Combination Therapy vs. Standard Therapy for Glioblastoma Patients Completed NCT01149109 Phase 3 Temozolomide and lomustine;Temozolomide
42 A Study of Bevacizumab (Avastin®) in Combination With Temozolomide and Radiotherapy in Participants With Newly Diagnosed Glioblastoma Completed NCT00943826 Phase 3 Bevacizumab;Temozolomide;Placebo
43 Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM) Completed NCT00916409 Phase 3 Temozolomide
44 Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma Completed NCT00884741 Phase 3 Temozolomide
45 Standard Radiation Therapy, Higher-Dose Radiation Therapy, or Chemotherapy in Treating Older Patients With Glioblastoma Multiforme Completed NCT00820963 Phase 3 temozolomide
46 Clinical Trial to Assess the Efficacy and Safety of 'INNOCELL Immuncell-LC' With Temozolomide in Newly Diagnosed Glioblastoma of Korea Completed NCT00807027 Phase 3 Activated T lymphocyte(Immuncell-LC)
47 Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma Completed NCT00777153 Phase 3 Cediranib;Cediranib;Lomustine Chemotherapy;Placebo Cediranib
48 Nimotuzumab in Adults With Glioblastoma Multiforma Completed NCT00753246 Phase 3 nimotuzumab
49 Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status Completed NCT00689221 Phase 3 Cilengitide;Temozolomide
50 Radiation Therapy With or Without Temozolomide in Treating Older Patients With Newly Diagnosed Glioblastoma Multiforme Completed NCT00482677 Phase 3 temozolomide

Search NIH Clinical Center for Astrocytoma

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: astrocytoma

Genetic Tests for Astrocytoma

Genetic tests related to Astrocytoma:

# Genetic test Affiliating Genes
1 Astrocytoma 29

Anatomical Context for Astrocytoma

MalaCards organs/tissues related to Astrocytoma:

41
Brain, Spinal Cord, T Cells, Endothelial, Testes, Bone, Breast

Publications for Astrocytoma

Articles related to Astrocytoma:

(show top 50) (show all 2350)
# Title Authors Year
1
Absence of 1p/19q codeletion in oligodendroglioma-like areas of pilocytic astrocytomas. ( 29595124 )
2018
2
Long-term outcomes of primarily metastatic juvenile pilocytic astrocytoma in children. ( 29125440 )
2018
3
iASPP, a microRNAa89124 target, is aberrantly expressed in astrocytoma and regulatesA malignantA gliomaA cellA migration and viability. ( 29257240 )
2018
4
Trapped ventricle after laser ablation of a subependymal giant cell astrocytoma complicated by intraventricular gadolinium extravasation: case report. ( 29451453 )
2018
5
Intermediate Pilomyxoid Astrocytoma in the Cerebellum of a 5-Year-Old Boy. ( 29717569 )
2018
6
Supratentorial extension of large cerebellar pilocytic astrocytoma in adult. ( 29446978 )
2018
7
MicroRNA-370 suppresses the progression and proliferation of human astrocytoma and glioblastoma by negatively regulating I^-catenin and causing activation of FOXO3a. ( 29399110 )
2018
8
Reader response: Pilocytic astrocytoma with anaplasia arising from the optic chiasm in a very elderly patient. ( 29807920 )
2018
9
Durable response to bevacizumab in adults with recurrent pilocytic astrocytoma. ( 29629823 )
2018
10
Cystathionine Promotes the Proliferation of Human Astrocytoma U373 Cells. ( 29848703 )
2018
11
Management and survival of adult patients with pilocytic astrocytoma in the National Cancer Database. ( 29427814 )
2018
12
Long-Term Remission of Recurrent Brainstem Pilocytic Astrocytoma with Neuraxis Dissemination Using Recombinant Human Endostatin After Failure of Vincristine and Carboplatin. ( 29203315 )
2018
13
Phosphoglycerate mutase 1 is highly expressed in C6 glioma cells and human astrocytoma. ( 29805628 )
2018
14
Adult Pilocytic Astrocytoma: An Institutional Series and Systematic Literature Review for Extent of Resection and Recurrence. ( 29180079 )
2018
15
Co-occurrence of astrocytoma and astroblastoma: Case report and literature review. ( 29939429 )
2018
16
Giant congenital melanocytic nevus associated with cerebellar astrocytoma. ( 29619995 )
2018
17
Pilocytic astrocytoma with leptomeningeal spread in a patient with incontinentia pigmenti presenting with unilateral nystagmus. ( 29171168 )
2018
18
An elderly case of malignant small cell glioma with hemorrhage coexistent with a calcified pilocytic astrocytoma component in the cerebellar hemisphere. ( 29851180 )
2018
19
CDKN2A/B Loss Is Associated with Anaplastic Transformation in a Case of NTRK2 Fusion-positive Pilocytic Astrocytoma. ( 29804288 )
2018
20
Diagnostic accuracy of diffusion weighted imaging for differentiation of supratentorial pilocytic astrocytoma and pleomorphic xanthoastrocytoma. ( 29797290 )
2018
21
A low-grade astrocytoma in a sixteen-year-old boy with a 7q11.22 deletion. ( 29445462 )
2018
22
Pilocytic astrocytoma with spontaneous malignant transformation with intracranial and skeletal dissemination: case report and review of the literature. ( 29745267 )
2018
23
Combined Diffuse Astrocytoma and Pleomorphic Xanthoastrocytoma grade III sharing IDH1 R132H mutation. ( 29859360 )
2018
24
MR Imaging Features of Anaplastic Pleomorphic Xanthoastrocytoma Mimicking High-Grade Astrocytoma. ( 29903923 )
2018
25
Dysembryoplastic neuroepithelial tumor-like pilocytic astrocytoma: A case report. ( 29768357 )
2018
26
Rare compound heterozygous variants in PNKP identified by whole exome sequencing in a German patient with ataxia-oculomotor apraxia 4 and pilocytic astrocytoma. ( 29498415 )
2018
27
Efficacy and safety of everolimus in patients younger than 12a8^months with congenital subependymal giant cell astrocytoma. ( 29395661 )
2018
28
Novel suprasellar location of desmoplastic infantile astrocytoma and ganglioglioma: a single institution's experience. ( 29979130 )
2018
29
Pediatric cerebellar pilocytic astrocytoma presenting with spontaneous intratumoral hemorrhage. ( 29569086 )
2018
30
Atypical subependymal giant cell astrocytoma and neonatal tuberous sclerosis. ( 29555882 )
2018
31
Effect of everolimus on skin lesions in patients treated for subependymal giant cell astrocytoma and renal angiomyolipoma: final 4-year results from the randomised EXIST-1 and EXIST-2 studies. ( 29569806 )
2018
32
High-level Sp1 is Associated with Proliferation, Invasion, and Poor Prognosis in Astrocytoma. ( 29948615 )
2018
33
The effect of everolimus on renal angiomyolipoma in pediatric patients with tuberous sclerosis being treated for subependymal giant cell astrocytoma. ( 28993887 )
2018
34
Simultaneous supratentorial and infratentorial pilocytic astrocytoma in an adult patient with concurrent neurofibromatosis type 1 and HIV infection. ( 29908379 )
2018
35
Desmoplastic non- infantile astrocytoma/Ganglioglioma: rare low-grade tumor with frequent BRAF V600E mutation. ( 29902580 )
2018
36
Expression of CD133 as a Putative Prognostic Biomarker to Predict Intracranial Dissemination of Primary Spinal Cord Astrocytoma. ( 29180077 )
2018
37
Mitogen-activated protein kinase in gliosis and pilocytic astrocytoma. ( 29168690 )
2018
38
Hypoxia Detection in Infiltrative Astrocytoma: Ferumoxytol-based Quantitative BOLD MRI with Intraoperative and Histologic Validation. ( 29944077 )
2018
39
<i>FGFR1</i> tyrosine kinase domain duplication in pilocytic astrocytoma with anaplasia. ( 29610389 )
2018
40
Delayed leptomeningeal metastasis of an adult anaplastic pilocytic astrocytoma. ( 29330645 )
2018
41
Subependymal giant cell astrocytoma-like astrocytoma: a neoplasm with a distinct phenotype and frequent neurofibromatosis type-1-association. ( 29973652 )
2018
42
Effect of brefelamide on proliferation of 1321N1 human astrocytoma cells induced by glial cell line-derived neurotrophic factor. ( 29441947 )
2018
43
Stachydrine suppresses viability &amp;amp; migration of astrocytoma cells via CXCR4/ERK &amp;amp; CXCR4/Akt pathway activity. ( 29873242 )
2018
44
Editors' note: Pilocytic astrocytoma with anaplasia arising from the optic chiasm in a very elderly patient. ( 29807919 )
2018
45
Pseudoprogression successfully treated with bevacizumab in a child with spinal pilocytic astrocytoma. ( 29804214 )
2018
46
Spinal cord astrocytoma: a unique presentation of abdominal pain. ( 29487669 )
2018
47
Lacunar Stroke, Cavernous Angioma, and Fusiform Aneurysm Due to Irradiation for Pilocytic Astrocytoma-A Case Report. ( 29673614 )
2018
48
Intraorbital ancient pilocytic astrocytoma of the optic nerve in neurofibromatosis type 1 patient presenting with sudden ocular pain. ( 29511546 )
2018
49
Orbital tumor associated with a microphthalmic eye and colobomatous cleft: Pilocytic astrocytoma (glioma) or massive retinal gliosis. ( 29755278 )
2018
50
Circulating serum oncologic miRNA in pediatric juvenile pilocytic astrocytoma patients predicts mural nodule volume. ( 29911246 )
2018

Variations for Astrocytoma

ClinVar genetic disease variations for Astrocytoma:

6
(show all 35)
# Gene Variation Type Significance SNP ID Assembly Location
1 PTPN11 NM_002834.4(PTPN11): c.226G> A (p.Glu76Lys) single nucleotide variant Pathogenic rs121918464 GRCh37 Chromosome 12, 112888210: 112888210
2 PTPN11 NM_002834.4(PTPN11): c.226G> A (p.Glu76Lys) single nucleotide variant Pathogenic rs121918464 GRCh38 Chromosome 12, 112450406: 112450406
3 PTPN11 NM_002834.4(PTPN11): c.227A> G (p.Glu76Gly) single nucleotide variant Pathogenic rs121918465 GRCh37 Chromosome 12, 112888211: 112888211
4 PTPN11 NM_002834.4(PTPN11): c.227A> G (p.Glu76Gly) single nucleotide variant Pathogenic rs121918465 GRCh38 Chromosome 12, 112450407: 112450407
5 PTPN11 NM_002834.4(PTPN11): c.227A> C (p.Glu76Ala) single nucleotide variant Pathogenic rs121918465 GRCh37 Chromosome 12, 112888211: 112888211
6 PTPN11 NM_002834.4(PTPN11): c.227A> C (p.Glu76Ala) single nucleotide variant Pathogenic rs121918465 GRCh38 Chromosome 12, 112450407: 112450407
7 IDH1 NM_001282386.1(IDH1): c.395G> A (p.Arg132His) single nucleotide variant Pathogenic/Likely pathogenic rs121913500 GRCh38 Chromosome 2, 208248388: 208248388
8 IDH1 NM_001282386.1(IDH1): c.395G> A (p.Arg132His) single nucleotide variant Pathogenic/Likely pathogenic rs121913500 GRCh37 Chromosome 2, 209113112: 209113112
9 FGFR1 NM_023110.2(FGFR1): c.1638C> A (p.Asn546Lys) single nucleotide variant Pathogenic rs779707422 GRCh37 Chromosome 8, 38274849: 38274849
10 FGFR1 NM_023110.2(FGFR1): c.1638C> A (p.Asn546Lys) single nucleotide variant Pathogenic rs779707422 GRCh38 Chromosome 8, 38417331: 38417331
11 FGFR1 NM_023110.2(FGFR1): c.1966A> G (p.Lys656Glu) single nucleotide variant Pathogenic/Likely pathogenic rs869320694 GRCh37 Chromosome 8, 38272308: 38272308
12 FGFR1 NM_023110.2(FGFR1): c.1966A> G (p.Lys656Glu) single nucleotide variant Pathogenic/Likely pathogenic rs869320694 GRCh38 Chromosome 8, 38414790: 38414790
13 IDH1 NM_001282387.1(IDH1): c.394C> T (p.Arg132Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913499 GRCh37 Chromosome 2, 209113113: 209113113
14 IDH1 NM_001282387.1(IDH1): c.394C> T (p.Arg132Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913499 GRCh38 Chromosome 2, 208248389: 208248389
15 IDH1 NM_001282387.1(IDH1): c.394C> A (p.Arg132Ser) single nucleotide variant Pathogenic/Likely pathogenic rs121913499 GRCh37 Chromosome 2, 209113113: 209113113
16 IDH1 NM_001282387.1(IDH1): c.394C> A (p.Arg132Ser) single nucleotide variant Pathogenic/Likely pathogenic rs121913499 GRCh38 Chromosome 2, 208248389: 208248389
17 FGFR1 NM_023110.2(FGFR1): c.1968G> C (p.Lys656Asn) single nucleotide variant Likely pathogenic rs1057519897 GRCh37 Chromosome 8, 38272306: 38272306
18 FGFR1 NM_023110.2(FGFR1): c.1968G> C (p.Lys656Asn) single nucleotide variant Likely pathogenic rs1057519897 GRCh38 Chromosome 8, 38414788: 38414788
19 FGFR1 NM_023110.2(FGFR1): c.1636A> G (p.Asn546Asp) single nucleotide variant Likely pathogenic rs1057519898 GRCh37 Chromosome 8, 38274851: 38274851
20 FGFR1 NM_023110.2(FGFR1): c.1636A> G (p.Asn546Asp) single nucleotide variant Likely pathogenic rs1057519898 GRCh38 Chromosome 8, 38417333: 38417333
21 FGFR1 NM_023110.2(FGFR1): c.1543A> G (p.Met515Val) single nucleotide variant Likely pathogenic rs1057519899 GRCh37 Chromosome 8, 38275397: 38275397
22 FGFR1 NM_023110.2(FGFR1): c.1543A> G (p.Met515Val) single nucleotide variant Likely pathogenic rs1057519899 GRCh38 Chromosome 8, 38417879: 38417879
23 H3F3A NM_002107.4(H3F3A): c.83A> T (p.Lys28Met) single nucleotide variant Likely pathogenic rs1057519903 GRCh37 Chromosome 1, 226252135: 226252135
24 H3F3A NM_002107.4(H3F3A): c.83A> T (p.Lys28Met) single nucleotide variant Likely pathogenic rs1057519903 GRCh38 Chromosome 1, 226064434: 226064434
25 ARID1A NM_006015.5(ARID1A): c.60_62dup (p.Pro21_Ser22insPro) duplication Conflicting interpretations of pathogenicity rs748085214 GRCh37 Chromosome 1, 27022954: 27022956
26 ARID1A NM_006015.5(ARID1A): c.60_62dup (p.Pro21_Ser22insPro) duplication Conflicting interpretations of pathogenicity rs748085214 GRCh38 Chromosome 1, 26696463: 26696465
27 ARID1B NM_020732.3(ARID1B): c.751T> G (p.Cys251Gly) single nucleotide variant Uncertain significance GRCh37 Chromosome 6, 157099814: 157099814
28 ARID1B NM_020732.3(ARID1B): c.751T> G (p.Cys251Gly) single nucleotide variant Uncertain significance GRCh38 Chromosome 6, 156778680: 156778680
29 EPHA5 NM_004439.7(EPHA5): c.1043A> G (p.Asp348Gly) single nucleotide variant Uncertain significance rs200932017 GRCh38 Chromosome 4, 65495411: 65495411
30 EPHA5 NM_004439.7(EPHA5): c.1043A> G (p.Asp348Gly) single nucleotide variant Uncertain significance rs200932017 GRCh37 Chromosome 4, 66361129: 66361129
31 KMT2D NM_003482.3(KMT2D): c.15876G> C (p.Glu5292Asp) single nucleotide variant Uncertain significance GRCh37 Chromosome 12, 49418638: 49418638
32 KMT2D NM_003482.3(KMT2D): c.15876G> C (p.Glu5292Asp) single nucleotide variant Uncertain significance GRCh38 Chromosome 12, 49024855: 49024855
33 NC_000014.9: g.38411139_38421941dup duplication Likely pathogenic GRCh38 Chromosome 14, 38411139: 38421941
34 TSC1 NM_000368.4(TSC1): c.359T> C (p.Leu120Pro) single nucleotide variant Uncertain significance GRCh38 Chromosome 9, 132925591: 132925591
35 TSC1 NM_000368.4(TSC1): c.359T> C (p.Leu120Pro) single nucleotide variant Uncertain significance GRCh37 Chromosome 9, 135800978: 135800978

Cosmic variations for Astrocytoma:

9
(show top 50) (show all 5804)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM40802 ZW10 central nervous system,brain,glioma,astrocytoma Grade III c.2140C>T p.P714S 11:113736699-113736699 4
2 COSM40801 ZSWIM4 central nervous system,brain,glioma,astrocytoma Grade III c.266C>T p.P89L 19:13799832-13799832 4
3 COSM6932117 ZRSR2 central nervous system,brain,glioma,astrocytoma Grade III c.271G>A p.E91K 23:15803755-15803755 4
4 COSM6948317 ZRSR2 central nervous system,brain,glioma,astrocytoma Grade III c.340C>T p.Q114* 23:15804138-15804138 4
5 COSM6959574 ZRSR2 central nervous system,brain,glioma,astrocytoma Grade III c.260G>A p.R87K 23:15803744-15803744 4
6 COSM6932118 ZRSR2 central nervous system,brain,glioma,astrocytoma Grade III c.961C>T p.P321S 23:15822754-15822754 4
7 COSM39611 ZPLD1 central nervous system,brain,glioma,astrocytoma Grade III c.393A>T p.G131G 3:102456210-102456210 4
8 COSM40237 ZNF687 central nervous system,brain,glioma,astrocytoma Grade III c.3651C>T p.T1217T 1:151291146-151291146 4
9 COSM39318 ZNF687 central nervous system,brain,glioma,astrocytoma Grade III c.2044T>A p.C682S 1:151288335-151288335 4
10 COSM39317 ZNF687 central nervous system,brain,glioma,astrocytoma Grade III c.2043G>C p.Q681H 1:151288334-151288334 4
11 COSM39149 ZNF507 central nervous system,brain,glioma,astrocytoma Grade III c.1517G>C p.R506T 19:32354347-32354347 4
12 COSM40794 ZNF473 central nervous system,brain,glioma,astrocytoma Grade III c.42C>T p.D14D 19:50039193-50039193 4
13 COSM39217 ZMYND8 central nervous system,brain,glioma,astrocytoma Grade III c.2162T>G p.V721G 20:47246130-47246130 4
14 COSM40504 ZMYND8 central nervous system,brain,glioma,astrocytoma Grade III c.2176G>A p.D726N 20:47246116-47246116 4
15 COSM39507 ZMAT4 central nervous system,brain,glioma,astrocytoma Grade III c.76G>A p.E26K 8:40825601-40825601 4
16 COSM6976869 ZFHX3 central nervous system,brain,glioma,astrocytoma Grade III c.4279G>A p.A1427T 16:72798403-72798403 4
17 COSM6929045 ZFHX3 central nervous system,brain,glioma,astrocytoma Grade III c.3607G>T p.E1203* 16:72811961-72811961 4
18 COSM6959528 ZFHX3 central nervous system,brain,glioma,astrocytoma Grade III c.145C>T p.P49S 16:72960001-72960001 4
19 COSM5385367 ZFHX3 central nervous system,brain,glioma,astrocytoma Grade III c.934G>A p.D312N 16:72959212-72959212 4
20 COSM5981027 ZFHX3 central nervous system,brain,glioma,astrocytoma Grade III c.8647A>G p.M2883V 16:72794035-72794035 4
21 COSM3888943 ZFHX3 central nervous system,brain,glioma,astrocytoma Grade III c.8198G>A p.R2733H 16:72794484-72794484 4
22 COSM6976870 ZFHX3 central nervous system,brain,glioma,astrocytoma Grade III c.461G>A p.G154E 16:72959685-72959685 4
23 COSM6948292 ZFHX3 central nervous system,brain,glioma,astrocytoma Grade III c.1819G>A p.E607K 16:72958327-72958327 4
24 COSM40870 ZFC3H1 central nervous system,brain,glioma,astrocytoma Grade III c.1055G>A p.S352N 12:71647774-71647774 4
25 COSM40793 ZFAT central nervous system,brain,glioma,astrocytoma Grade III c.1006G>A p.V336M 8:134602677-134602677 4
26 COSM40680 ZEB1 central nervous system,brain,glioma,astrocytoma Grade III c.1913C>T p.S638L 10:31521248-31521248 4
27 COSM41152 ZC3H6 central nervous system,brain,glioma,astrocytoma Grade III c.2254G>T p.G752* 2:112331172-112331172 4
28 COSM40778 ZBTB4 central nervous system,brain,glioma,astrocytoma Grade III c.2842C>T p.L948F 17:7462140-7462140 4
29 COSM40777 ZBTB24 central nervous system,brain,glioma,astrocytoma Grade III c.1886C>T p.P629L 6:109466059-109466059 4
30 COSM39508 ZBTB21 central nervous system,brain,glioma,astrocytoma Grade III c.997G>A p.G333S 21:41993099-41993099 4
31 COSM40776 ZBTB16 central nervous system,brain,glioma,astrocytoma Grade III c.413C>T p.A138V 11:114063713-114063713 4
32 COSM41039 YWHAH central nervous system,brain,glioma,astrocytoma Grade III c.169C>T p.R57* 22:31956220-31956220 4
33 COSM40774 YTHDC2 central nervous system,brain,glioma,astrocytoma Grade III c.782C>T p.A261V 5:113532985-113532985 4
34 COSM4440509 YES1 central nervous system,brain,glioma,astrocytoma Grade III c.832C>T p.R278* 18:743308-743308 4
35 COSM6913717 YES1 central nervous system,brain,glioma,astrocytoma Grade III c.1153G>A p.A385T 18:736946-736946 4
36 COSM6962767 YAP1 central nervous system,brain,glioma,astrocytoma Grade III c.538G>A p.A180T 11:102114360-102114360 4
37 COSM6931893 YAP1 central nervous system,brain,glioma,astrocytoma Grade III c.1007C>T p.T336I 11:102227474-102227474 4
38 COSM6928995 YAP1 central nervous system,brain,glioma,astrocytoma Grade III c.842G>A p.R281Q 11:102206046-102206046 4
39 COSM6976817 XRCC2 central nervous system,brain,glioma,astrocytoma Grade III c.365G>A p.S122N 7:152649120-152649120 4
40 COSM39272 XPO7 central nervous system,brain,glioma,astrocytoma Grade III c.1157G>A p.R386Q 8:21982692-21982692 4
41 COSM6931627 XPO1 central nervous system,brain,glioma,astrocytoma Grade III c.551G>A p.G184E 2:61499752-61499752 4
42 COSM6962233 XPO1 central nervous system,brain,glioma,astrocytoma Grade III c.1192C>G p.Q398E 2:61493947-61493947 4
43 COSM6981708 XPO1 central nervous system,brain,glioma,astrocytoma Grade III c.319G>T p.V107F 2:61502293-61502293 4
44 COSM6930402 XPO1 central nervous system,brain,glioma,astrocytoma Grade III c.2855T>C p.L952S 2:61482497-61482497 4
45 COSM40772 XPO1 central nervous system,brain,glioma,astrocytoma Grade III c.1147G>A p.E383K 2:61493992-61493992 4
46 COSM6976397 XPO1 central nervous system,brain,glioma,astrocytoma Grade III c.28G>A p.D10N 2:61533870-61533870 4
47 COSM6932148 XIAP central nervous system,brain,glioma,astrocytoma Grade III c.227G>A p.G76E 23:123885889-123885889 4
48 COSM6927664 XIAP central nervous system,brain,glioma,astrocytoma Grade III c.184C>T p.R62W 23:123885846-123885846 4
49 COSM6912189 XIAP central nervous system,brain,glioma,astrocytoma Grade III c.1057-2A>T p.? 23:123892729-123892729 4
50 COSM21780 XAB2 central nervous system,brain,glioma,astrocytoma Grade III c.849C>A p.I283I 19:7624419-7624419 4

Copy number variations for Astrocytoma from CNVD:

7 (show top 50) (show all 436)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13337 1 1 124300000 Loss Astrocytoma
2 13347 1 1 125000000 Deletion Astrocytoma
3 13376 1 1 2300000 Amplification AURKAIP1 Astrocytoma
4 13377 1 1 2300000 Amplification C1orf159 Astrocytoma
5 13378 1 1 2300000 Amplification CDC2L1 Astrocytoma
6 13379 1 1 2300000 Amplification CDC2L2 Astrocytoma
7 13380 1 1 2300000 Amplification CPSF3L Astrocytoma
8 13381 1 1 2300000 Amplification GNB1 Astrocytoma
9 13382 1 1 2300000 Amplification HES4 Astrocytoma
10 13383 1 1 2300000 Amplification ISG15 Astrocytoma
11 13386 1 1 2300000 Amplification MIB2 Astrocytoma
12 13387 1 1 2300000 Amplification MMP23A Astrocytoma
13 13388 1 1 2300000 Amplification NOC2L Astrocytoma
14 13389 1 1 2300000 Amplification PRKCZ Astrocytoma
15 13390 1 1 2300000 Amplification SDF4 Astrocytoma
16 13391 1 1 2300000 Amplification SLC35E2 Astrocytoma
17 13757 1 1 28000000 Deletion Astrocytoma
18 13760 1 1 28000000 Deletion Astrocytoma
19 16428 1 124300000 247249719 Gain Astrocytoma
20 16544 1 12700000 16200000 Deletion Astrocytoma
21 30468 1 243700000 249250621 Deletion AKT3 Astrocytoma
22 30469 1 243700000 249250621 Deletion SDCCAG8 Astrocytoma
23 30470 1 243700000 249250621 Deletion ZNF238 Astrocytoma
24 31970 1 32400000 34600000 Deletion Astrocytoma
25 32218 1 34600000 44100000 Deletion Astrocytoma
26 35014 1 59000000 68900000 Deletion Astrocytoma
27 36950 1 8384389 8404226 Deletion SLC45A1 Astrocytoma
28 46536 10 82000000 135374737 Loss Astrocytoma
29 48496 11 1 52900000 Loss Astrocytoma
30 67045 12 35400000 132349534 Loss Astrocytoma
31 67785 12 44600000 69800000 Gain Astrocytoma
32 75152 13 16000000 114142980 Loss Astrocytoma
33 89238 15 17000000 100338915 Gain Astrocytoma
34 97277 16 1 38200000 Loss Astrocytoma
35 97302 16 1 6300000 Amplification ABCA3 Astrocytoma
36 97303 16 1 6300000 Amplification AXIN1 Astrocytoma
37 97304 16 1 6300000 Amplification C1QTNF8 Astrocytoma
38 97305 16 1 6300000 Amplification CACNA1H Astrocytoma
39 97306 16 1 6300000 Amplification CREBBP Astrocytoma
40 97307 16 1 6300000 Amplification DNAJA3 Astrocytoma
41 97308 16 1 6300000 Amplification HMOX2 Astrocytoma
42 97309 16 1 6300000 Amplification IGFALS Astrocytoma
43 97310 16 1 6300000 Amplification MAGMAS Astrocytoma
44 97311 16 1 6300000 Amplification MAPK8IP3 Astrocytoma
45 97312 16 1 6300000 Amplification MMP25 Astrocytoma
46 97313 16 1 6300000 Amplification MPG Astrocytoma
47 97314 16 1 6300000 Amplification MRPL28 Astrocytoma
48 97315 16 1 6300000 Amplification MSLN Astrocytoma
49 97316 16 1 6300000 Amplification NME4 Astrocytoma
50 97317 16 1 6300000 Amplification NTHL1 Astrocytoma

Expression for Astrocytoma

Search GEO for disease gene expression data for Astrocytoma.

Pathways for Astrocytoma

GO Terms for Astrocytoma

Biological processes related to Astrocytoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of protein kinase B signaling GO:0051897 9.13 FGFR1 MIR21 PTPN11
2 positive regulation of vascular endothelial cell proliferation GO:1905564 8.62 FGFR1 MIR21

Sources for Astrocytoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....